Philadelphia, Pa — TREND Community, a digital health company that uses AI technology to advance understanding of diseases from patient and caregiver conversations on social
To use a screen reader, the text is copied below: 2019 Annual Letter Dear Community, 2019 was a year of discovery and progress for TREND.
Rare diseases are not all that rare—it’s a paradox we hear all the time. With more than 7,000 known examples, and upwards of 25 million
Patient-centricity is bound to be one of the most ubiquitous industry buzzwords of 2020. Every party involved in healthcare has a vested interest in more
TREND is very excited to have contributed to Kiniksa’s application for Breakthrough Therapy designation, which was awarded by the FDA for rilonacept for the treatment
It is easy to regard an individual rare disease as an affliction that only impacts a small number of people, but rare diseases affect hundreds
To continue bridging the gap between patient communities and the industries that serve them, TREND began a search for a writer to help them manage
Yesterday, Harmony Biosciences announced FDA Approval Of WAKIX (pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy. Read
TREND Community invites patients and caregivers living with recurrent pericarditis to share their stories and experiences. Interested community members will participate in moderated online discussions
Last month, TREND Community partnered with the Pitt Hopkins Research Foundation to create a custom Community Voice Report for the “PARENTS of Pitt Hopkins” Facebook
